AnaptysBio (NASDAQ:ANAB) Stock Price Down 4.9% – Here’s Why

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) were down 4.9% during trading on Tuesday . The company traded as low as $32.95 and last traded at $33.03. Approximately 48,018 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 324,649 shares. The stock had previously closed at $34.74.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ANAB shares. JPMorgan Chase & Co. boosted their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Wedbush restated an “outperform” rating and issued a $42.00 target price on shares of AnaptysBio in a research note on Thursday, September 26th. Truist Financial upped their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of AnaptysBio in a research note on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.10.

AnaptysBio Trading Up 1.4 %

The business’s 50-day moving average is $35.35 and its two-hundred day moving average is $29.14. The firm has a market cap of $961.08 million, a P/E ratio of -5.65 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The business had revenue of $10.97 million for the quarter, compared to the consensus estimate of $25.85 million. On average, analysts anticipate that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Insider Activity at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was purchased at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the transaction, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock valued at $892,936 in the last quarter. Insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. nVerses Capital LLC boosted its holdings in shares of AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares in the last quarter. Duncan Williams Asset Management LLC bought a new position in shares of AnaptysBio in the third quarter valued at approximately $282,000. SG Americas Securities LLC bought a new position in shares of AnaptysBio in the third quarter valued at approximately $405,000. Algert Global LLC boosted its holdings in shares of AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after acquiring an additional 1,078 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its holdings in shares of AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after acquiring an additional 1,265,891 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.